🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05426720
Recruiting Observational

Risk Factors and Biomarkers for Post-tuberculosis Lung Damage

NCT05426720 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2022-01-01
Last updated
2022-06-22

Condition(s) studied

Pulmonary TB

Investigational drug(s) / intervention(s)

no intervention

no intervention: no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.

Study summary

This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.

Eligibility

Sex
MALE
Min age
25 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: Male patients aged 25-60 years newly diagnosed with active pulmonary TB. Exclusion Criteria: 1. patients with positive sputum smear or TB culture results; 2. human immunodeficiency virus-positive patients; 3. patients infected with multidrug-resistant TB; 4. patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases; 5. non-compliant patients who were unable to complete the lung function tests; 6. patients without lung parenchymal destruction (such as tuberculous pleurisy). -

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Peking University Third Hospital Beijing China Recruiting
Beijing Geriatric Hospital Beijing China Recruiting

More Peking University Third Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05426720 on ClinicalTrials.gov ↗ ← All trials in China